What is the safest selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) to use during pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Safest SSRI or SNRI in Pregnancy

Sertraline is the safest SSRI for use during pregnancy, with the lowest risk profile for persistent pulmonary hypertension of the newborn (PPHN) and established safety data, while paroxetine should be avoided due to FDA pregnancy category D classification for cardiac malformations. 1, 2

Primary Recommendation: Sertraline

Sertraline ranks as most likely to have the lowest risk for PPHN among SSRIs (P = .83) according to network meta-analysis, suggesting it has the best safety profile for pregnancy use 2. Additionally, sertraline is one of the most commonly prescribed antidepressants during both pregnancy and breastfeeding, reflecting its established safety record 1.

Medications to Avoid

Paroxetine carries the highest risk and should be avoided:

  • FDA classified paroxetine as pregnancy category D in 2005 due to concerns about congenital cardiac malformations 1
  • While more recent population-based studies (nearly 1 million pregnant women) suggest no link between first-trimester antidepressant use and cardiac malformations, the FDA classification remains 1

Class-Wide Risks to Discuss

All SSRIs and SNRIs carry some shared risks that must be weighed against untreated depression:

Persistent Pulmonary Hypertension of the Newborn (PPHN)

  • Risk increases with late pregnancy exposure (after 20 weeks): OR 2.08 (95% CI, 1.44-3.01) 2
  • Incidence: 2.9 cases per 1000 live births
  • Number needed to harm: 286-351 1
  • Critical caveat: FDA revised its 2006 advisory in 2011, stating conflicting findings make it unclear whether SSRIs actually cause PPHN 1

Neonatal Adaptation Syndrome

  • Occurs in hours to days after birth
  • Symptoms: continuous crying, irritability, jitteriness, tremors, hypertonia, tachypnea, feeding difficulty, hypoglycemia, seizures 3
  • Usually resolves within 1-2 weeks (up to 4 weeks with paroxetine) 3

Other Potential Risks

  • May increase risk of preterm delivery compared to untreated depressed women 1
  • Conflicting evidence on autism, ADHD, speech delay, and lower Apgar scores—high-quality evidence lacking 1

SNRIs in Pregnancy

SNRIs (duloxetine, venlafaxine) have slightly higher discontinuation rates due to adverse effects compared to SSRIs as a class (67% and 40% increased risk respectively) 1. Given limited pregnancy-specific data and higher side effect burden, SSRIs remain preferred first-line agents.

Clinical Algorithm

  1. First choice: Sertraline (lowest PPHN risk, extensive safety data)
  2. Alternative SSRIs: Fluoxetine, citalopram, escitalopram (avoid citalopram >40 mg/day due to QT prolongation) 1
  3. Avoid: Paroxetine (FDA category D)
  4. SNRIs: Reserve for cases where SSRIs have failed or are contraindicated

Essential Management Principles

  • Use monotherapy at the lowest effective dose 4
  • Consider therapeutic drug monitoring (TDM) during pregnancy due to pharmacokinetic changes across trimesters 4
  • Do not discontinue antidepressants in women with severe, recurrent depression—relapse risk is substantial 4
  • Arrange delivery at hospitals with specialized neonatal care units 4
  • Plan early follow-up after discharge to monitor for neonatal adaptation syndrome (first week of life) 3

Critical Context

Untreated depression carries significant risks: premature birth, decreased breastfeeding initiation, and ongoing maternal morbidity 1. The absolute risks from SSRI exposure remain small, and treatment decisions must balance medication risks against the substantial harms of untreated maternal depression. The risk of relapse with medication discontinuation often outweighs the small absolute risks of continued treatment 4.

Related Questions

What are the effects on newborns due to maternal Selective Serotonin Reuptake Inhibitor (SSRI) use?
What are the safest antidepressant options and dosing for a pregnant woman with major depressive disorder?
What SSRIs are recommended for a pregnant patient with depression, including dosing and safety considerations?
What are the indications, dosing regimen, contraindications, precautions, monitoring parameters, and drug interactions for amitriptyline?
For a pregnant patient with active suicidal ideation who has failed three selective serotonin reuptake inhibitors (SSRIs), what evidence‑based pharmacologic and non‑pharmacologic treatment options, including dosing and safety considerations, can be recommended?
Can lorazepam (Ativan) be administered sublingually for acute seizure control, and what dose should be used?
What is the appropriate starting dose and titration schedule for galantamine in an older adult with mild‑to‑moderate Alzheimer’s disease, including adjustments for renal or hepatic impairment and monitoring recommendations?
My relative is starting chemotherapy tomorrow and I am caring for a 15‑month‑old child with a runny nose and cough; I feel I am developing a cold. Besides avoiding contact with the patient, what additional infection‑control precautions should I take?
Where can I obtain a polygenic risk score (PRS) for atherosclerotic cardiovascular disease given my LDL‑C of 140 mg/dL and Lp(a) of 120 nmol/L?
What causes the sensation of the rectum collapsing against the vaginal wall?
What is the maximum recommended adult dose of diphenhydramine?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.